Seaport Therapeutics

Psychedelic medicine developer

Seaport Therapeutics is an active, Boston-based clinical-stage company developing neuropsychiatric medicines through its Glyph oral prodrug platform. Its pipeline includes investigational candidates at preclinical and clinical stages. The company’s psychedelic-related program, SPT-348, is preclinical. Its candidates are investigational and are not available to buy.

Website

seaporttx.com

Seaport Therapeutics catalog

All products · Psychedelic medicine pipeline

Shop the Seaport Therapeutics catalog

1 item across 1 shelf

Psychedelic medicine pipeline1 item

• SPT-348 (Glyph2BLSD) – Glyph 2-bromo-LSD, an oral prodrug of 2-bromo-LSDInvestigational